DPYD
ENSG00000188641
Target class
Enzyme
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- DPYD
- Gene name
- Dihydropyrimidine dehydrogenase
- Gene symbol
- DPYD
- Protein name
- Dihydropyrimidine dehydrogenase [NADP(+)] (DHPDHase) (DPD) (EC 1.3.1.2) (Dihydrothymine dehydrogenase) (Dihydrouracil dehydrogenase)
- DPD
- DHPDHase
- Gene biotype
- Protein coding
- Gene family
- Flavoproteins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 52
- Highest tissue expression
- 43.02
- Tissue specificity (Gini)
- 0.432
- Tissue specificity (tau)
- 0.745
- KEGG gene identifiers
- hsa:1806
- Reactome pathways
- R-HSA-73621
- Protein interaction confidence
- 0.837286
- Protein interaction partners
- 49
- End position
- 97995000
- Start position
- 97077743
- Chromosome
- 1
- Strand
- Reverse
- Cytoplasm.
- Tissue specificity (tau)
- 0.744893
- Expression inequality (Gini)
- 0.432214
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 43.02
- Lung
- 29.63
- Adipose - Visceral (Omentum)
- 23.99
- Adipose - Subcutaneous
- 23.28
- Cervix - Ectocervix
- 23.04
Expression in transcripts per million
- Cells - Cultured fibroblasts43.02
- Lung29.63
- Adipose - Visceral (Omentum)23.99
- Adipose - Subcutaneous23.28
- Cervix - Ectocervix23.04
- Artery - Coronary22.22
- Vagina21.57
- Ovary21.33
- Artery - Tibial21.08
- Cervix - Endocervix20.41
- Nerve - Tibial20.16
- Whole Blood20.11
- Uterus19.49
- Spleen19.28
- Breast - Mammary Tissue19.13
- Bladder17.69
- Colon - Sigmoid16.94
- Fallopian Tube16.62
- Thyroid15.17
- Artery - Aorta15.13
- Esophagus - Gastroesophageal Junction14.13
- Esophagus - Mucosa13.82
- Minor Salivary Gland13.14
- Esophagus - Muscularis13.07
- Liver12.42
And 29 more, listed on the interactive page.
- GO:0006145
- GO:0006208
- GO:0006210
- GO:0006212
- GO:0006214
- GO:0042178
- GO:0046045
- GO:0046050
- GO:0005737
- GO:0005829
- GO:0005515
- GO:0017113
- GO:0042803
Related records
Trials (20)
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
- A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
- A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
- CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer
- Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer
- DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
- Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
- Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
- Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial
- Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer
- Eniluracil Hand Foot Syndrome
- Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
- Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
- Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
- Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
- Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma
Drugs (2)
- Eniluracil Dihydropyrimidine dehydrogenase inhibitor
- Gimeracil Dihydropyrimidine dehydrogenase inhibitor